Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings.
Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K.
Sasaki R, et al.
Cancers (Basel). 2019 Nov 10;11(11):1769. doi: 10.3390/cancers11111769.
Cancers (Basel). 2019.
PMID: 31717674
Free PMC article.